Clinical significance of an anti-Di^b assessed by flow cytometry

1.Thompson PR, Childers DM, Hatcher DE. Anti-Di^b— first and second examples. Vox Sang 1967;13:314–8.10.1111/j.1423-0410.1967.tb03114.xSearch in Google Scholar

2.Nakajima H, Hayakawa Z, Ito H. A new example of anti-Di^b found in a Japanese woman. Vox Sang 1971;20:271–3.Search in Google Scholar

3.Gottleib AM. Hemolytic disease of the newborn due to anti-Di^b. Vox Sang 1971;21:79–80.10.1111/j.1423-0410.1971.tb00560.xSearch in Google Scholar

4.Ishimori T, Fukumoto Y, Abe K, et al. Rare Diego blood group phenotype Di(a+b–). I. Anti-Di^b causing hemolytic disease of the newborn. Vox Sang 1976;31:61–3.Search in Google Scholar

5.Orlina AR, DiMauro J, Unger PJ. Hemolytic disease of the newborn due to anti-Di^b. Am J Clin Pathol 1979;71:713–4.10.1093/ajcp/71.6.713Search in Google Scholar

6.Postoway N, Nance S, O’Neill P, Garratty G. Comparison of a practical differential agglutination procedure to flow cytometry in following the survival of transfused red cells (abstract). Transfusion 1985;25:453.Search in Google Scholar

7.Valinsky JE, Marsh WL, Bianco C. Flow cytometric procedure for estimation of transfused erythrocyte survival “in vivo” (abstract). Transfusion 1985;25:478.Search in Google Scholar

8.Read EJ, Crabill HE, Davey RJ. Flow cytometric determination of transfused red blood cell (RBC) survival in a patient with autoimmune hemolytic anemia (AIHA) (abstract). Transfusion 1985;25:451.Search in Google Scholar

9.Nance S, Gonzalez B, Postoway N, Vengelen-Tyler V, Garratty G. Clinical significance of a primarily complement-dependent anti-Jk^a in a patient who received Jk(a+) red cells (abstract). Transfusion 1985;25:482.Search in Google Scholar

10.DiNapoli J, Gingras A, Diggs E, Alicea-Tossas E, Kessler L. Survival of Ge+ red cells in a patient with anti- Ge1,2: data from ⁵¹Cr, flow cytometric, IgG subclass, and monocyte erythrophagocytosis assays (abstract). Transfusion 1986;26:545.Search in Google Scholar

11.Ratcliff D, Fiorenza S, Culotta E, Arndt P, Garratty G. Hydrops fetalis (HF) and a maternal hemolytic transfusion reaction associated with anti-Js^b (abstract). Transfusion 1987;27:534.Search in Google Scholar

12.Issitt PD, Valinsky JE, Marsh WL, DiNapoli J, Gutgsell NS. In vivo red cell destruction by anti-Lu6. Transfusion 1990;30:258–60.10.1046/j.1537-2995.1990.30390194349.xSearch in Google Scholar

13.Garratty G, Arndt P, Co A, Rodberg K, Furmanski M. Fatal hemolytic transfusion reaction resulting from ABO mistyping of a patient with acquired B antigen detectable only by some monoclonal anti-B reagents. Transfusion 1996;36:351–7.10.1046/j.1537-2995.1996.36496226152.xSearch in Google Scholar

14.Vengelen-Tyler V, ed. Technical manual. 12th ed. Bethesda, MD: American Association of Blood Banks, 1996.Search in Google Scholar

15.Petz LD, Garratty G. Acquired immune hemolytic anemias. New York: Churchill Livingstone, 1980.Search in Google Scholar

16.Nance SJ, Garratty G. Application of flow cytometry to immunohematology. J Immunol Methods 1987;101:127–31.10.1016/0022-1759(87)90225-0Search in Google Scholar

17.Garratty G, Arndt P. Applications of flow cytofluorometry to transfusion science. Transfusion 1995;35:157–78.10.1046/j.1537-2995.1995.35295125739.x7825212Search in Google Scholar

18.Mollison PL, Engelfreit CP, Contreras M. Blood transfusion in clinical medicine. 9th ed. Oxford: Blackwell Scientific Publications, 1993:792–3;348.Search in Google Scholar

19.Garratty G. Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of transfusion reactions: a technical workshop. Arlington, VA: American Association of Blood Banks, 1982;91–119.Search in Google Scholar

20.Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449–52.10.1046/j.1537-2995.1987.27688071692.x3686653Search in Google Scholar

21.Postoway N, Garratty G. Standardization of IgG subclass antiserums for use with sensitized red cells. Transfusion 1983;23:398–400.10.1046/j.1537-2995.1983.23584018719.x6623608Search in Google Scholar

22.Nance SJ, Arndt PA, Garratty G. The effect of fresh normal serum on monocyte monolayer assay reactivity (letter). Transfusion 1988;28:398–9.10.1046/j.1537-2995.1988.28488265281.x3388490Search in Google Scholar

23.Levy GJ, Selset G, McQuiston D, et al. Clinical significance of anti-Yt^b. Transfusion 1988;28:265–7.10.1046/j.1537-2995.1988.28388219157.xSearch in Google Scholar

24.Judd WJ, Oberman HA, Silenieks A, Steiner EA. Clinical significance of anti-Lan (letter). Transfusion 1984;24:181.10.1046/j.1537-2995.1984.24284173358.xSearch in Google Scholar

25.Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Trans Med Rev 1990;IV:297–312.10.1016/S0887-7963(90)70272-6Search in Google Scholar

26.Thompson JC, Shulman IA, Nelson JM, Okamoto M, Strautz R. Life-saving incompatible blood transfusion. Lab Med 1987;18:385–7.10.1093/labmed/18.6.385Search in Google Scholar